Modified VSV Matrix Proteins for Temperature-Sensitive Vaccine Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current VSV vectors face challenges in achieving high-titer replication while maintaining avirulence, temperature sensitivity, and resistance to reversion to wild-type phenotype, necessitating a safer and effective vaccine vector system.
Innovation Solution
Development of non-cytolytic and avirulent recombinant vesicular stomatitis viruses (rVSV) with modified matrix proteins, such as rVSVInd (G21E/M51R/L111A) and rVSVNJ (G22E/M48R/M51R), which replicate at 31°C but fail to assemble at 37°C, inducing robust immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If VSV vectors are used to achieve high-titer replication, then productivity is improved, but reliability deteriorates due to reversion to wild-type phenotype and cytopathic effects
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions in the M protein (G21E, L111A, M51R) that fundamentally alter the virus's temperature sensitivity profile and cytopathic properties. These parameter changes in the protein sequence create a stable attenuated phenotype that prevents reversion while maintaining replication capability at permissive temperatures.
Solution Approach 2:
The invention creates a composite viral system by combining multiple mutations (G21E, L111A, M51R) within the M protein to achieve a synergistic effect. This composite approach integrates temperature sensitivity, reduced cytopathic effects, and assembly defects at non-permissive temperatures into a single stabilized viral vector platform.
2Object-affected harmful factors
If temperature sensitivity is introduced to reduce virulence, then object-affected harmful factors are reduced, but device complexity increases due to multiple mutations required
Solution Approach 1:
The patent merges multiple functional requirements into a single protein target (the M protein). By combining temperature sensitivity, reduced cytopathic effects, and assembly regulation all within the M protein through specific amino acid substitutions, the invention simplifies the overall viral vector design while achieving multiple safety and performance goals simultaneously.
3Productivity
If replication capability is enhanced for vaccine effectiveness, then productivity is improved, but object-generated harmful factors increase due to potential reversion and cytopathic effects
Solution Approach 1:
The invention applies parameter changes by modifying the M protein sequence (G21E, L111A, M51R) to create a temperature-dependent replication profile. This allows the virus to replicate efficiently at permissive temperatures (31°C) for vaccine production and immunogenicity, while automatically shutting down at non-permissive temperatures (37°C) to prevent reversion and reduce cytopathic effects in vivo.
Data Source
Figure 1
Figure 1G~10N
Figure 2
AI summary
The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to alanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). These new rVSVs having the mutant M are significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31°C, and of poor replication or incapable of replication at about 37°C or higher.